Neuroprotection of Pioglitazone in Acute Ischemic Stroke
NCT ID: NCT02195791
Last Updated: 2017-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
4 participants
INTERVENTIONAL
2014-07-31
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke
NCT04123067
Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database
NCT05817097
DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes
NCT07241897
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
NCT00272909
Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke
NCT02059785
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pioglitazone
Pioglitazone
Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days
Placebo
Placebo
Placebo (oral) 1 tab once daily for 7 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pioglitazone
Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days
Placebo
Placebo (oral) 1 tab once daily for 7 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age≧20 years
3. Stroke severity with at least one point for limb weakness in National Institutes of Health Stroke Scale (NIHSS).
4. The patients with no known history of diabetes with admission serum glucose ≧130 mg/dl.
Exclusion Criteria
2. The patients who have history of congestive heart failure or myocardial infarction.
3. The patients who have known history of using pioglitazone before the onset of stroke.
4. The patients who have mRS≧3 before stroke onset.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taipei Medical University Shuang Ho Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nai-Fang Chi, MD
Role: PRINCIPAL_INVESTIGATOR
Taipei Medical University Shuang Ho Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Taipei Medical Universtiy- Shuang Ho Hospital
New Taipei City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MOHW103-TDU-B-212-113001 S
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.